参考文献/References:
[1]Geisinger E,Huo W,Hernandez-Bird J,et al.Acinetobacter baumannii : Envelope Determinants That Control Drug Resistance, Virulence, and Surface Variability[J].Annu Rev Microbiol,2019,73(1):481-506.[2]Khazaal SS,Al-Kadmy IMS,Aziz SN.Mechanism of pathogenesis in multidrug resistant Acinetobacter baumannii isolated from intensive care unit[J].J Gene Reports,2020,18(3):100557.[3]王玉巧,王萍,何琼,等.某医院ICU鲍曼不动杆菌感染的耐药性及抗菌药物使用临床研究[J].宁夏医学杂志,2020,42(8):742-744.[4]胡付品,郭燕,朱德妹,等.2019年CHINET三级医院细菌耐药监测[J].中国感染与化疗杂志,2020,20(3):233-243.[5]Chakravarty B.Genetic mechanisms of antibiotic resistance and virulence in Acinetobacter baumannii:background,challenges and future prospects[J].Mol Biol Rep,2020,47(5):4037-4046.[6]Skariyachan S,Taskeen N,Ganta M,et al.Recent perspectives on the virulent factors and treatment options for multidrug-resistant Acinetobacter baumannii[J].Crit Rev Microbiol,2019,45(3):315-333.[7]Lee CR,Lee JH,Park M,et al.Biology of Acinetobacter baumannii:Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options[J].Front Cell Infect Microbiol,2017(7):55.[8]Wareth G,Brandt C,Sprague LD,et al.Acinetobacter baumanniiSpatio-Temporal Distribution of in Germany-A Comprehensive Systematic Review of Studies on Resistance Development in Humans(2000-2018)[J].Microorganisms,2020,8(3):375.[9]Chen Y,Gao J,Zhang H,et al.Spread of the blaOXA-23-Containing Tn2008 in Carbapenem-Resistant Acinetobacter baumannii Isolates Grouped in CC92 from China[J].Front Microbiol,2017(8):163.[10]Abdi SN,Ghotaslou R,Ganbarov K,et al.Acinetobacter baumannii Efflux Pumps and Antibiotic Resistance[J].Infect Drug Resist,2020(13):423-434.[11]Verma P,Tiwari V.Targeting Outer Membrane Protein Component AdeC for the Discovery of Efflux Pump Inhibitor against AdeABC Efflux Pump of Multidrug Resistant Acinetobacter baumannii[J].Cell Biochem Biophys,2018,76(3):391-400.[12]吴萌萌,徐家根,梅亚宁.鲍曼不动杆菌细胞内的舒巴坦浓度与外膜蛋白表达相关性研究[J].中国临床药理学杂志,2016(20):1897-1900.[13]Yang N,Liu Y,He P,et al.iTRAQ-Based Differential Proteomic Analysis Reveals the Pathways Associated with Tigecycline Resistance in Acinetobacter baumannii[J].Cell Physiol Biochem,2018,51(3):1327-1339.[14]Krzysciak P,Chmielarczyk A,Pobiega M,et al.Acinetobacter baumannii isolated from hospital-acquired infection: biofilm production and drug susceptibility[J].APMIS,2017,125(11):1017-1026.[15]Peng Q,Lin F,Ling B.In vitro activity of biofilm inhibitors in combination with antibacterial drugs against extensively drug-resistant Acinetobacter baumannii[J].Sci Rep,2020,10(1):18097.[16]Saipriya K,Swathi C,Ratnakar KS,et al.Quorum-sensing system in Acinetobacter baumannii: a potential target for new drug development[J].J Appl Microbiol,2020,128(1):15-27.[17]Harding CM,Hennon SW,Feldman MF.Uncovering the mechanisms of Acinetobacter baumannii virulence[J].Nat Rev Microbiol,2018,16(2):91-102.[18]Piperaki E,Tzouvelekis L,Miriagou V,et al.Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment[J].Clin Microbiol Infect,2019,25(8):951-957.[19]Chen H,Liu Q,Chen Z,et al.Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis[J].J Infect Chemother,2017,23(5):278-285.[20]Liu J,Zhu F,Feng B,et al.Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis[J].J Glob Antimicrob Resist,2021,24(8):136-147.[21]Reza M,Mohsen H,Aghil B,et al.Evaluation of Polymyxin B Susceptibility Profile and Detection of Drug Resistance Genes among Acinetobacter Baumannii Clinical Isolates in Tehran, Iran during 2015-2016[J].Mediterr J Hematol Infect Dis,2018,10(1):e2018044.[22]黄靖宇,黄华,方威,等.多粘菌素B联合其它抗生素治疗IRAB及IRPAE感染有效性研究[J].汕头大学医学院学报,2017,30(4):231-232,244.[23]Oliva A,Garzoli S,De Angelis M,et al.In-Vitro Evaluation of Different Antimicrobial Combinations with and without Colistin Against Carbapenem-Resistant Acinetobacter Baumannii[J].Molecules,2019,24(5):886.[24]Wu H,Liu W,Zhu M,et al.Research and analysis of 74 bloodstream infection cases of Acinetobacter baumannii and drug resistance[J].Eur Rev Med Pharmacol Sci,2018,22(6):1782-1786.[25]王梦鹤,明德松.替加环素和头孢哌酮/舒巴坦钠单独及联合治疗泛耐药鲍曼不动杆菌感染的经济学分析[J].检验医学与临床,2020,17(10):1421-1424.[26]Neshani A,Sedighian H,Mirhosseini S,et al.Antimicrobial peptides as a promising treatment option against Acinetobacter baumannii infections[J].Microb Pathog,2020,146(5):104238.[27]Karakonstantis S,Kritsotakis E,Gikas A.Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems[J].Infection,2020,48(6):835-851.[28]Madadi-Goli N,Moniri R,Bagheri-Josheghani S,et al.Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii[J].Iran J Microbiol,2017,9(1):19-25.
相似文献/References:
[1]李淑惠.鲍曼不动杆菌临床分布及耐药性分析[J].医学信息,2018,31(03):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
LI Shu-hui.Clinical Distribution and Drug Resistance of Acinetobacter Baumannii[J].Medical Information,2018,31(03):165.[doi:10.3969/j.issn.1006-1959.2018.03.061]
[2]李佳颖,李春霖,王玉莹,等.鲍曼不动杆菌的单药治疗及其联合使用的研究[J].医学信息,2019,32(05):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
LI Jia-ying,LI Chun-lin,WANG Yu-ying,et al.Monotherapy of Acinetobacter Baumannii and Its Combined Use[J].Medical Information,2019,32(03):48.[doi:10.3969/j.issn.1006-1959.2019.05.016]
[3]常 琪,魏韵佳,穆 琪,等.2016~2018年鲍曼不动杆菌临床分离株的
分布特征及耐药性变迁[J].医学信息,2019,32(16):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
CHANG Qi,WEI Yun-jia,MU Qi,et al.Distribution Characteristics and Drug Resistance Changes of Clinical Isolates of
Acinetobacter Baumannii from 2016 to 2018[J].Medical Information,2019,32(03):119.[doi:10.3969/j.issn.1006-1959.2019.16.038]
[4]李 冲,赵 云,王 昊,等.ICU鲍曼不动杆菌血流感染临床特征及预后危险因素分析[J].医学信息,2020,33(13):54.[doi:10.3969/j.issn.1006-1959.2020.13.015]
LI Chong,ZHAO Yun,WANG Hao,et al.Clinical Characteristics and Prognostic Risk Factors of Bloodstream Infection of Acinetobacter Baumannii in ICU[J].Medical Information,2020,33(03):54.[doi:10.3969/j.issn.1006-1959.2020.13.015]
[5]刘婕妤,杨文杰,赵学群.T淋巴细胞亚群对鲍曼不动杆菌感染与定植的诊断价值[J].医学信息,2021,34(20):167.[doi:10.3969/j.issn.1006-1959.2021.20.045]
LIU Jie-yu,YANG Wen-jie,ZHAO Xue-qun.Diagnostic Value of T Lymphocyte Subsets in Acinetobacter Baumannii Infection and Colonization[J].Medical Information,2021,34(03):167.[doi:10.3969/j.issn.1006-1959.2021.20.045]